187 related articles for article (PubMed ID: 31000698)
1. BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition.
Del Gaudio N; Di Costanzo A; Liu NQ; Conte L; Migliaccio A; Vermeulen M; Martens JHA; Stunnenberg HG; Nebbioso A; Altucci L
Cell Death Dis; 2019 Apr; 10(5):338. PubMed ID: 31000698
[TBL] [Abstract][Full Text] [Related]
2. The ncBAF Complex Regulates Transcription in AML Through H3K27ac Sensing by BRD9.
Klein DC; Lardo SM; Hainer SJ
Cancer Res Commun; 2024 Jan; 4(1):237-252. PubMed ID: 38126767
[TBL] [Abstract][Full Text] [Related]
3. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
4. STAT5A regulates DNMT3A in CD34(+)/CD38(-) AML cells.
Takeuchi A; Nishioka C; Ikezoe T; Yang J; Yokoyama A
Leuk Res; 2015 Aug; 39(8):897-905. PubMed ID: 26059451
[TBL] [Abstract][Full Text] [Related]
5. BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma.
Weisberg E; Chowdhury B; Meng C; Case AE; Ni W; Garg S; Sattler M; Azab AK; Sun J; Muz B; Sanchez D; Toure A; Stone RM; Galinsky I; Winer E; Gleim S; Gkountela S; Kedves A; Harrington E; Abrams T; Zoller T; Vaupel A; Manley P; Faller M; Chung B; Chen X; Busenhart P; Stephan C; Calkins K; Bonenfant D; Thoma CR; Forrester W; Griffin JD
Blood Cancer J; 2022 Jul; 12(7):110. PubMed ID: 35853853
[TBL] [Abstract][Full Text] [Related]
6. IL-1β inhibits self-renewal capacity of dormant CD34⁺/CD38⁻ acute myelogenous leukemia cells in vitro and in vivo.
Yang J; Ikezoe T; Nishioka C; Nobumoto A; Yokoyama A
Int J Cancer; 2013 Oct; 133(8):1967-81. PubMed ID: 23564444
[TBL] [Abstract][Full Text] [Related]
7. CD82 regulates STAT5/IL-10 and supports survival of acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Yang J; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
Int J Cancer; 2014 Jan; 134(1):55-64. PubMed ID: 23797738
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition.
Hohmann AF; Martin LJ; Minder JL; Roe JS; Shi J; Steurer S; Bader G; McConnell D; Pearson M; Gerstberger T; Gottschamel T; Thompson D; Suzuki Y; Koegl M; Vakoc CR
Nat Chem Biol; 2016 Sep; 12(9):672-9. PubMed ID: 27376689
[TBL] [Abstract][Full Text] [Related]
9. Helicase-like transcription factor is a RUNX1 target whose downregulation promotes genomic instability and correlates with complex cytogenetic features in acute myeloid leukemia.
Cheng CK; Chan NP; Wan TS; Lam LY; Cheung CH; Wong TH; Ip RK; Wong RS; Ng MH
Haematologica; 2016 Apr; 101(4):448-57. PubMed ID: 26802049
[TBL] [Abstract][Full Text] [Related]
10. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract][Full Text] [Related]
11. The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34
Murone M; Radpour R; Attinger A; Chessex AV; Huguenin AL; Schürch CM; Banz Y; Sengupta S; Aguet M; Rigotti S; Bachhav Y; Massière F; Ramachandra M; McAllister A; Riether C
Mol Cancer Ther; 2017 Aug; 16(8):1497-1510. PubMed ID: 28468777
[TBL] [Abstract][Full Text] [Related]
12. Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted "hsa-miR-2278" as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A.
Kaymaz BT; Günel NS; Ceyhan M; Çetintaş VB; Özel B; Yandım MK; Kıpçak S; Aktan Ç; Gökbulut AA; Baran Y; Can BK
Tumour Biol; 2015 Sep; 36(10):7915-27. PubMed ID: 25953263
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic modulation by targeting bromodomain containing protein 9 (BRD9): Its therapeutic potential and selective inhibition.
Ali MM; Naz S; Ashraf S; Knapp S; Ul-Haq Z
Int J Biol Macromol; 2023 Mar; 230():123428. PubMed ID: 36709803
[TBL] [Abstract][Full Text] [Related]
14. Targeting GLI1 Suppresses Cell Growth and Enhances Chemosensitivity in CD34+ Enriched Acute Myeloid Leukemia Progenitor Cells.
Long B; Wang LX; Zheng FM; Lai SP; Xu DR; Hu Y; Lin DJ; Zhang XZ; Dong L; Long ZJ; Tong XZ; Liu Q
Cell Physiol Biochem; 2016; 38(4):1288-302. PubMed ID: 27008269
[TBL] [Abstract][Full Text] [Related]
15. Bromodomain-Containing Protein 9 Regulates Signaling Pathways and Reprograms the Epigenome in Immortalized Human Uterine Fibroid Cells.
Yang Q; Vafaei S; Falahati A; Khosh A; Bariani MV; Omran MM; Bai T; Siblini H; Ali M; He C; Boyer TG; Al-Hendy A
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255982
[TBL] [Abstract][Full Text] [Related]
16. Targeting BRD9 by I-BRD9 efficiently inhibits growth of acute myeloid leukemia cells.
Zhou L; Yao Q; Li H; Chen J
Transl Cancer Res; 2021 Jul; 10(7):3364-3372. PubMed ID: 35116642
[TBL] [Abstract][Full Text] [Related]
17. Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours.
Chen Y; Gao Z; Mohd-Ibrahim I; Yang H; Wu L; Fu Y; Deng Y
Clin Transl Med; 2024 Feb; 14(2):e1543. PubMed ID: 38303608
[TBL] [Abstract][Full Text] [Related]
18. BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors.
Wang X; Wang S; Troisi EC; Howard TP; Haswell JR; Wolf BK; Hawk WH; Ramos P; Oberlick EM; Tzvetkov EP; Ross A; Vazquez F; Hahn WC; Park PJ; Roberts CWM
Nat Commun; 2019 Apr; 10(1):1881. PubMed ID: 31015438
[TBL] [Abstract][Full Text] [Related]
19. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
[TBL] [Abstract][Full Text] [Related]
20. Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia.
Huang S; Pan J; Jin J; Li C; Li X; Huang J; Huang X; Yan X; Li F; Yu M; Hu C; Jin J; Xu Y; Ling Q; Ye W; Wang Y; Jin J
Cancer Lett; 2019 Oct; 461():132-143. PubMed ID: 31310800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
